查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1965971

宠物疫苗市场－全球产业规模、份额、趋势、机会和预测：按动物类型、疫苗类型、给药方法、地区和竞争格局划分，2021-2031年

Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Vaccination, By Mode Of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球宠物疫苗市场预计将从 2025 年的 21.4 亿美元成长到 2031 年的 30.9 亿美元，复合年增长率为 6.31%。

这些生物製药旨在激发伴侣动物的免疫反应，产生抗体，从而增强其对多种病毒、细菌和寄生虫性行为感染的免疫力。成长要素的关键因素包括通用感染疾病风险的增加以及全球宠物饲养量的激增，凸显了定期预防性兽医护理的必要性。此外，政府对狂犬病控制的严格监管以及宠物人性化的趋势也促使人们更加遵守疫苗接种计划。例如，根据澳洲动物医学协会发布的《2025年报告》，73%的澳洲家庭拥有宠物，显示已开发地区高宠物饲养率正在推动对兽用生技药品的需求。

市场概览
预测期 2027-2031
市场规模：2025年 21.4亿美元
市场规模：2031年 30.9亿美元
复合年增长率：2026-2031年 6.31%
成长最快的细分市场 口服
最大的市场 北美洲

然而，兽医服务成本的不断上涨常常阻碍市场发展，这对注重预算的宠物饲主构成了巨大的经济负担。常规健康检查和疫苗接种的高昂费用常常导致治疗延误，并难以坚持每年的加强免疫接种计划。这种经济压力，加上长途运输过程中维持低温运输的物流挑战，仍是全球宠物疫苗市场持续成长的主要障碍。

市场驱动因素

伴侣动物日益人性化是推动市场扩张的主要动力，显着影响人们对预防性医疗保健解决方案的需求以及疫苗接种计划的依从性。随着饲主越来越将宠物视为家庭成员，他们对宠物健康和寿命的重视程度也日益提高，促使人们更加严格地遵守细菌和病毒威胁的疫苗接种通讯协定。这种文化转变有效地扩大了生物製药的潜在市场，确保了更多宠物获得定期照护。宠物数量庞大；根据2024年3月发布的《英国宠物食品和宠物数据报告2024》，英国宠物总数已达3600万隻，凸显了需要定期兽医护理的动物数量庞大。

同时，兽医保健产业的成长也推动了市场发展，促进了优质创新疫苗产品的广泛应用。饲主越来越愿意在医疗服务上投入大量资金，这抵消了潜在的成本障碍，并推动了产业价值的成长。根据美国宠物用品协会于2025年3月发布的《2025年产业趋势报告》，美国每年在兽医保健和产品销售方面的支出预计将达到414亿美元，显示人们对维护动物健康有着浓厚的兴趣。与兽医专业人士的积极互动进一步增强了这项经济贡献。根据澳洲动物医学协会于2025年9月发布的《澳洲宠物2025》报告，89%的犬隻和75%的猫在过去一年中曾就诊于兽医，这表明较高的就诊率，从而确保了製造商的持续收入。

市场挑战

兽医服务成本的不断上涨是全球宠物疫苗市场扩张的主要障碍。随着日常动物保健费用的增加，精打细算的饲主越来越倾向于选择紧急治疗而非疫苗接种等预防措施。这种经济压力阻碍了有效免疫计划所需的持续护理，导致疫苗接种总量下降。当健康检查费用过高时，饲主往往会推迟这些必要的就诊，使兽医错失了为宠物接种必要的年度加强疫苗以维持免疫水平的机会。

因此，预防保健的延误会直接导致市场需求萎缩。如果饲主未能遵守建议的疫苗接种计划，群体免疫力就会受损，疫苗生产商的产生收入也会停滞不前。根据美国兽医协会（AVMA）2025年的数据，兽医服务价格上涨了5.7%，而就诊患者数量较去年同期下降了3%。成本上升与诊所就诊量下降之间的这种相关性表明，经济问题正在严重阻碍该行业在已开发地区和新兴地区保持稳定成长的能力。

市场趋势

慢性疾病治疗性疫苗的商业化正在从根本上改变全球宠物疫苗市场，将免疫接种的重点从预防感染疾病扩展到主动管理复杂的非传染性疾病，例如肿瘤。製造商正积极利用自体和精准免疫疗法技术开发生物製药，以激发伴侣动物的免疫系统攻击肿瘤特异性抗原。这项临床进展为兽医提供了针对末期疾病的有效介入方案，而先前针对末期病患的治疗选择十分有限。例如，Toligen Pharmaceuticals公司于2025年2月发布的新闻稿题为“宠物抗癌新希望”，其中指出，接受该公司靶向自体癌症疫苗治疗的转移性血管肉瘤犬的总体生存率比仅接受手术的犬组提高了3.5倍，这凸显了老年宠物对治疗性生技药品日益增长的依赖性。

同时，随着重组疫苗和次单位疫苗平台的发展，产业格局也在发生变化，越来越多的公司为了提高安全性和扩大生产规模，开始放弃传统的活病毒疫苗技术。这一趋势凸显了高纯度抗原和高分子量生技药品的研发，而对生物製程基础设施的大量资本投入对于确保供应链稳定至关重要。主要企业的努力也体现了这种向先进平台技术的策略转型。 2025年5月，默克动物保健公司宣布投资8.95亿美元扩建位于堪萨斯州德索託的工厂，以提高其高分子量疫苗和生技药品的产能。此类投资凸显了市场对先进递送系统的关注，这些系统能够提高疫苗的疗效并降低伴侣动物的副作用风险。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球宠物疫苗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 动物种类（狗、猫、马）
    • 疫苗类型（犬类、猫科动物、其他）
    • 依给药途径（注射疫苗、经鼻吸入型疫苗）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美宠物疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲宠物疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区宠物疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲宠物疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美宠物疫苗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球宠物疫苗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Zoetis Inc.
  • Bioveta as
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac SA
  • Zendal Group
  • Elanco Animal Health Incorporated

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19025

The Global Pet Vaccine Market is projected to expand from a valuation of USD 2.14 Billion in 2025 to USD 3.09 Billion by 2031, registering a CAGR of 6.31%. These biological preparations are engineered to trigger immune responses in companion animals, generating antibodies that confer immunity against various viral, bacterial, and parasitic infections. Key growth factors include the increasing incidence of zoonotic risks and a surge in global pet adoption, which underscores the need for regular preventative veterinary attention. Additionally, strict government regulations concerning rabies control, alongside the trend of pet humanization, drive higher adherence to vaccination schedules. For instance, Animal Medicines Australia reported in 2025 that 73% of Australian households possessed a pet, highlighting the strong ownership rates that fuel demand for veterinary biologicals in developed regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.14 Billion
Market Size 2031USD 3.09 Billion
CAGR 2026-20316.31%
Fastest Growing SegmentOral
Largest MarketNorth America

However, market progress is often hindered by the rising expense of veterinary services, which creates economic obstacles for budget-conscious pet owners. The substantial costs linked to routine wellness check-ups and vaccine administration frequently result in delayed treatments or failure to adhere to annual booster timelines. This financial limitation, combined with logistical difficulties in preserving cold-chain integrity during transport to isolated regions, persists as a major impediment to the consistent expansion of the global pet vaccine sector.

Market Driver

The increasing humanization of companion animals serves as a major engine for market expansion, heavily impacting the demand for preventative health solutions and adherence to immunization plans. As owners increasingly regard their pets as essential family members, they are more disposed to prioritize their health and lifespan, resulting in stricter compliance with vaccination protocols against bacterial and viral dangers. This cultural evolution effectively broadens the potential market for biologicals by ensuring a greater share of the pet population obtains regular care. The scale of this ownership base is significant; UK Pet Food's 'Pet Data Report 2024' from March 2024 noted that the United Kingdom's total pet population stood at 36 million, emphasizing the immense number of animals needing regular veterinary care.

Simultaneously, rising spending on veterinary healthcare supports the market by enabling the uptake of premium and innovative vaccine products. The growing readiness of owners to dedicate substantial funds to medical services helps offset potential cost hurdles, fostering value growth within the industry. According to the American Pet Products Association's 'State of the Industry 2025' report released in March 2025, annual expenditures on veterinary care and product sales in the United States were anticipated to hit $41.4 billion, signaling a strong commitment to animal wellness. This financial dedication is reinforced by active engagement with veterinary experts; Animal Medicines Australia's 'Pets in Australia 2025' report from September 2025 indicated that 89% of dogs and 75% of cats visited a veterinarian in the prior year, illustrating the high compliance levels that secure recurring revenue for manufacturers.

Market Challenge

The escalating cost of veterinary services constitutes a major barrier to the expansion of the global pet vaccine market. As the financial weight of routine animal healthcare increases, budget-conscious owners are frequently compelled to choose urgent medical treatments over preventative actions like vaccination. This economic pressure disrupts the continuity of care necessary for effective immunization regimens, causing a decrease in the total volume of vaccines administered. When wellness exams become too costly, owners often postpone these essential visits, leading to missed chances for veterinarians to provide required annual boosters and sustain immunity levels.

Consequently, this pattern of delayed maintenance leads to a direct contraction in market demand. When owners fail to maintain recommended vaccination schedules, it undermines herd immunity and stalls revenue generation for vaccine producers. Data from the American Veterinary Medical Association in 2025 showed that veterinary service prices rose by 5.7 percent, coinciding with a 3 percent year-over-year drop in patient visits. This link between increasing costs and reduced clinic attendance illustrates how affordability issues significantly hinder the industry's capacity to sustain steady growth rates in both developed and emerging regions.

Market Trends

The commercialization of therapeutic vaccines for chronic conditions is fundamentally transforming the Global Pet Vaccine Market by broadening the focus of immunization from infectious disease prevention to the active management of complex, non-infectious ailments such as oncology. Manufacturers are increasingly utilizing autologous and precision immunotherapy technologies to develop biologicals that prompt a companion animal's immune system to attack tumor-specific antigens. This clinical advancement offers veterinarians effective interventions for terminal conditions that previously had few options. For example, a February 2025 press release from Torigen Pharmaceuticals regarding 'New Hope For Pets In The Fight Against Cancer' reported that dogs with metastatic hemangiosarcoma treated with their targeted autologous cancer vaccine showed a 3.5-fold increase in overall survival compared to those receiving surgery alone, validating the rising reliance on therapeutic biologicals for aging pets.

At the same time, the shift toward recombinant and subunit vaccine platforms is altering the industry's manufacturing landscape as companies move away from conventional live-attenuated techniques to improve safety and production scalability. This trend emphasizes the creation of high-purity antigens and large-molecule biologicals, requiring significant capital investments in bioprocessing infrastructure to guarantee supply chain stability. This strategic move to advanced platform technologies is demonstrated by major industrial commitments; in May 2025, Merck Animal Health announced an investment of $895 million to expand its De Soto, Kansas facility to boost production capacity for large molecule vaccines and biologics. Such expenditures highlight the market's dedication to sophisticated delivery systems that provide enhanced potency and lower risks of adverse reactions in companion animals.

Key Market Players

  • Zoetis Inc.
  • Bioveta a.s
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac S.A.
  • Zendal Group
  • Elanco Animal Health Incorporated

Report Scope

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type

  • Canine
  • Feline
  • Equine

Pet Vaccine Market, By Vaccination

  • Canine Family
  • Feline Family
  • Others

Pet Vaccine Market, By Mode Of Administration

  • Injectable Vaccines
  • Intranasal Vaccines

Pet Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pet Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Canine, Feline, Equine)
    • 5.2.2. By Vaccination (Canine Family, Feline Family, Others)
    • 5.2.3. By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pet Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Vaccination
    • 6.2.3. By Mode Of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pet Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Vaccination
        • 6.3.1.2.3. By Mode Of Administration
    • 6.3.2. Canada Pet Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Vaccination
        • 6.3.2.2.3. By Mode Of Administration
    • 6.3.3. Mexico Pet Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Vaccination
        • 6.3.3.2.3. By Mode Of Administration

7. Europe Pet Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Vaccination
    • 7.2.3. By Mode Of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pet Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Vaccination
        • 7.3.1.2.3. By Mode Of Administration
    • 7.3.2. France Pet Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Vaccination
        • 7.3.2.2.3. By Mode Of Administration
    • 7.3.3. United Kingdom Pet Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Vaccination
        • 7.3.3.2.3. By Mode Of Administration
    • 7.3.4. Italy Pet Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Vaccination
        • 7.3.4.2.3. By Mode Of Administration
    • 7.3.5. Spain Pet Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Vaccination
        • 7.3.5.2.3. By Mode Of Administration

8. Asia Pacific Pet Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Vaccination
    • 8.2.3. By Mode Of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pet Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Vaccination
        • 8.3.1.2.3. By Mode Of Administration
    • 8.3.2. India Pet Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Vaccination
        • 8.3.2.2.3. By Mode Of Administration
    • 8.3.3. Japan Pet Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Vaccination
        • 8.3.3.2.3. By Mode Of Administration
    • 8.3.4. South Korea Pet Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Vaccination
        • 8.3.4.2.3. By Mode Of Administration
    • 8.3.5. Australia Pet Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Vaccination
        • 8.3.5.2.3. By Mode Of Administration

9. Middle East & Africa Pet Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Vaccination
    • 9.2.3. By Mode Of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pet Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Vaccination
        • 9.3.1.2.3. By Mode Of Administration
    • 9.3.2. UAE Pet Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Vaccination
        • 9.3.2.2.3. By Mode Of Administration
    • 9.3.3. South Africa Pet Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Vaccination
        • 9.3.3.2.3. By Mode Of Administration

10. South America Pet Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Vaccination
    • 10.2.3. By Mode Of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pet Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Vaccination
        • 10.3.1.2.3. By Mode Of Administration
    • 10.3.2. Colombia Pet Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Vaccination
        • 10.3.2.2.3. By Mode Of Administration
    • 10.3.3. Argentina Pet Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Vaccination
        • 10.3.3.2.3. By Mode Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pet Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bioveta a.s
  • 15.3. Hester Biosciences Limited
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Brilliant Bio Pharma Private Limited
  • 15.6. Heska Corporation
  • 15.7. Merck & Co., Inc.
  • 15.8. Virbac S.A.
  • 15.9. Zendal Group
  • 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer